yvandenbroek
/
sprookjes
/
Login
Register
TriplyDB
sprookjes
Browser
Triples
Insights
Schema
BETA
Class frequency
Class hierarchy
SPARQL
GraphQL
BETA
Graphs
2
Q31136560-D4ED499E-48B6-4996-BF3C-18CBBCB15F2B
Q31136560-D4ED499E-48B6-4996-BF3C-18CBBCB15F2B
BestRank
Statement
http://www.wikidata.org/entity/statement/Q31136560-D4ED499E-48B6-4996-BF3C-18CBBCB15F2B
Outcomes with two different schedules of bortezomib, melphalan, and prednisone (VMP) for previously untreated multiple myeloma: matched pair analysis using long-term follow-up data from the phase 3 VISTA and PETHEMA/GEM05 trials.
P2860
Q31136560-D4ED499E-48B6-4996-BF3C-18CBBCB15F2B
BestRank
Statement
http://www.wikidata.org/entity/statement/Q31136560-D4ED499E-48B6-4996-BF3C-18CBBCB15F2B
rank
NormalRank
type
BestRank
Statement
wasDerivedFrom
1fc14d56820c7434e27aabee4ce0d7e1d01b0471
P2860
Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study.